Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Author Correction: A mechanism for CO regulation of ion channels.

Kapetanaki SM, Burton MJ, Basran J, Uragami C, Moody PCE, Mitcheson JS, Schmid R, Davies NW, Dorlet P, Vos MH, Storey NM, Raven E.

Nat Commun. 2018 Aug 17;9(1):3354. doi: 10.1038/s41467-018-05622-6.

2.

A Novel Mechanism for Calmodulin-Dependent Inactivation of Transient Receptor Potential Vanilloid 6.

Bate N, Caves RE, Skinner SP, Goult BT, Basran J, Mitcheson JS, Vuister GW.

Biochemistry. 2018 May 8;57(18):2611-2622. doi: 10.1021/acs.biochem.7b01286. Epub 2018 Apr 13.

PMID:
29505720
3.

A mechanism for CO regulation of ion channels.

Kapetanaki SM, Burton MJ, Basran J, Uragami C, Moody PCE, Mitcheson JS, Schmid R, Davies NW, Dorlet P, Vos MH, Storey NM, Raven E.

Nat Commun. 2018 Mar 2;9(1):907. doi: 10.1038/s41467-018-03291-z. Erratum in: Nat Commun. 2018 Aug 17;9(1):3354.

4.

Modulation of hERG potassium channels by a novel small molecule activator.

Mitcheson JS, Hancox JC.

Br J Pharmacol. 2017 Oct;174(20):3669-3671. doi: 10.1111/bph.13964. Epub 2017 Sep 9. No abstract available.

5.

Calmodulin Regulates Human Ether à Go-Go 1 (hEAG1) Potassium Channels through Interactions of the Eag Domain with the Cyclic Nucleotide Binding Homology Domain.

Lörinczi E, Helliwell M, Finch A, Stansfeld PJ, Davies NW, Mahaut-Smith M, Muskett FW, Mitcheson JS.

J Biol Chem. 2016 Aug 19;291(34):17907-18. doi: 10.1074/jbc.M116.733576. Epub 2016 Jun 20.

6.

A heme-binding domain controls regulation of ATP-dependent potassium channels.

Burton MJ, Kapetanaki SM, Chernova T, Jamieson AG, Dorlet P, Santolini J, Moody PC, Mitcheson JS, Davies NW, Schmid R, Raven EL, Storey NM.

Proc Natl Acad Sci U S A. 2016 Apr 5;113(14):3785-90. doi: 10.1073/pnas.1600211113. Epub 2016 Mar 22.

7.

hERG potassium channel inhibition by ivabradine requires channel gating.

Melgari D, Brack KE, Zhang Y, El Harchi A, Mitcheson JS, Dempsey CE, Ng GA, Hancox JC.

J Mol Cell Cardiol. 2015 Oct;87:126-8. doi: 10.1016/j.yjmcc.2015.08.002. Epub 2015 Aug 11. No abstract available.

PMID:
26275355
8.

hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine.

Melgari D, Brack KE, Zhang C, Zhang Y, El Harchi A, Mitcheson JS, Dempsey CE, Ng GA, Hancox JC.

J Am Heart Assoc. 2015 Apr 24;4(4). pii: e001813. doi: 10.1161/JAHA.115.001813.

9.

New pyrimido-indole compound CD-160130 preferentially inhibits the KV11.1B isoform and produces antileukemic effects without cardiotoxicity.

Gasparoli L, D'Amico M, Masselli M, Pillozzi S, Caves R, Khuwaileh R, Tiedke W, Mugridge K, Pratesi A, Mitcheson JS, Basso G, Becchetti A, Arcangeli A.

Mol Pharmacol. 2015 Feb;87(2):183-96. doi: 10.1124/mol.114.094920. Epub 2014 Nov 19.

PMID:
25411366
10.

Long-term channel block is required to inhibit cellular transformation by human ether-à-go-go-related gene (hERG1) potassium channels.

Pier DM, Shehatou GS, Giblett S, Pullar CE, Trezise DJ, Pritchard CA, Challiss RA, Mitcheson JS.

Mol Pharmacol. 2014 Aug;86(2):211-21. doi: 10.1124/mol.113.091439. Epub 2014 May 15.

11.

Computational design and discovery of "minimally structured" hERG blockers.

Cavalli A, Buonfiglio R, Ianni C, Masetti M, Ceccarini L, Caves R, Chang MW, Mitcheson JS, Roberti M, Recanatini M.

J Med Chem. 2012 Apr 26;55(8):4010-4. doi: 10.1021/jm201194q. Epub 2012 Apr 6.

PMID:
22455383
12.

Mechanistic insight into human ether-à-go-go-related gene (hERG) K+ channel deactivation gating from the solution structure of the EAG domain.

Muskett FW, Thouta S, Thomson SJ, Bowen A, Stansfeld PJ, Mitcheson JS.

J Biol Chem. 2011 Feb 25;286(8):6184-91. doi: 10.1074/jbc.M110.199364. Epub 2010 Dec 6.

13.

Resonance assignment and secondary structure prediction of the N-terminal domain of hERG (Kv11.1).

Muskett FW, Mitcheson JS.

Biomol NMR Assign. 2011 Apr;5(1):15-7. doi: 10.1007/s12104-010-9256-3. Epub 2010 Aug 14.

PMID:
20711762
14.

Insight into the mechanism of inactivation and pH sensitivity in potassium channels from molecular dynamics simulations.

Stansfeld PJ, Grottesi A, Sands ZA, Sansom MS, Gedeck P, Gosling M, Cox B, Stanfield PR, Mitcheson JS, Sutcliffe MJ.

Biochemistry. 2008 Jul 15;47(28):7414-22. doi: 10.1021/bi800475j. Epub 2008 Jun 18.

PMID:
18558719
15.

hERG potassium channels and the structural basis of drug-induced arrhythmias.

Mitcheson JS.

Chem Res Toxicol. 2008 May;21(5):1005-10. doi: 10.1021/tx800035b. Epub 2008 May 1. Review.

PMID:
18447395
16.

Activation gating of hERG potassium channels: S6 glycines are not required as gating hinges.

Hardman RM, Stansfeld PJ, Dalibalta S, Sutcliffe MJ, Mitcheson JS.

J Biol Chem. 2007 Nov 2;282(44):31972-81. Epub 2007 Sep 6.

17.

Drug block of the hERG potassium channel: insight from modeling.

Stansfeld PJ, Gedeck P, Gosling M, Cox B, Mitcheson JS, Sutcliffe MJ.

Proteins. 2007 Aug 1;68(2):568-80.

PMID:
17444521
18.

Modulation of hERG potassium currents in HEK-293 cells by protein kinase C. Evidence for direct phosphorylation of pore forming subunits.

Cockerill SL, Tobin AB, Torrecilla I, Willars GB, Standen NB, Mitcheson JS.

J Physiol. 2007 Jun 1;581(Pt 2):479-93. Epub 2007 Mar 15.

20.

Molecular mechanisms for drug interactions with hERG that cause long QT syndrome.

Stansfeld PJ, Sutcliffe MJ, Mitcheson JS.

Expert Opin Drug Metab Toxicol. 2006 Feb;2(1):81-94. Review.

PMID:
16863470
21.

Molecular determinants of HERG channel block.

Kamiya K, Niwa R, Mitcheson JS, Sanguinetti MC.

Mol Pharmacol. 2006 May;69(5):1709-16. Epub 2006 Feb 10.

PMID:
16474003
22.

Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs.

Perry M, Stansfeld PJ, Leaney J, Wood C, de Groot MJ, Leishman D, Sutcliffe MJ, Mitcheson JS.

Mol Pharmacol. 2006 Feb;69(2):509-19. Epub 2005 Nov 16.

PMID:
16291873
23.

Direct block of human ether-a-go-go-related gene potassium channels by caffeine.

Cockerill SL, Mitcheson JS.

J Pharmacol Exp Ther. 2006 Feb;316(2):860-8. Epub 2005 Oct 14.

PMID:
16227470
24.

Predicting drug-hERG channel interactions that cause acquired long QT syndrome.

Sanguinetti MC, Mitcheson JS.

Trends Pharmacol Sci. 2005 Mar;26(3):119-24. Review.

PMID:
15749156
25.

The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.

Witchel HJ, Dempsey CE, Sessions RB, Perry M, Milnes JT, Hancox JC, Mitcheson JS.

Mol Pharmacol. 2004 Nov;66(5):1201-12. Epub 2004 Aug 12.

PMID:
15308760
26.

Molecular determinants of high-affinity drug binding to HERG channels.

Mitcheson JS, Perry MD.

Curr Opin Drug Discov Devel. 2003 Sep;6(5):667-74. Review.

PMID:
14579516
27.

Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes.

Witchel HJ, Milnes JT, Mitcheson JS, Hancox JC.

J Pharmacol Toxicol Methods. 2002 Sep-Oct;48(2):65-80. Review.

PMID:
14565563
28.

Drug binding to HERG channels: evidence for a 'non-aromatic' binding site for fluvoxamine.

Mitcheson JS.

Br J Pharmacol. 2003 Jul;139(5):883-4. Review. No abstract available.

29.

Comparison of Na(+)/Ca(2+) exchanger current and of its response to isoproterenol between acutely isolated and short-term cultured adult ventricular myocytes.

Pabbathi VK, Zhang YH, Mitcheson JS, Hinde AK, Perchenet L, Arberry LA, Levi AJ, Hancox JC.

Biochem Biophys Res Commun. 2002 Sep 20;297(2):302-8.

PMID:
12237118
30.

The S4-S5 linker couples voltage sensing and activation of pacemaker channels.

Chen J, Mitcheson JS, Tristani-Firouzi M, Lin M, Sanguinetti MC.

Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11277-82. Epub 2001 Sep 11.

31.

Open channel block of HERG K(+) channels by vesnarinone.

Kamiya K, Mitcheson JS, Yasui K, Kodama I, Sanguinetti MC.

Mol Pharmacol. 2001 Aug;60(2):244-53.

PMID:
11455010
32.

Molecular biology of K(+) channels and their role in cardiac arrhythmias.

Tristani-Firouzi M, Chen J, Mitcheson JS, Sanguinetti MC.

Am J Med. 2001 Jan;110(1):50-9. Review.

PMID:
11152866
33.

A structural basis for drug-induced long QT syndrome.

Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC.

Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12329-33.

34.

Functional roles of charged residues in the putative voltage sensor of the HCN2 pacemaker channel.

Chen J, Mitcheson JS, Lin M, Sanguinetti MC.

J Biol Chem. 2000 Nov 17;275(46):36465-71.

35.

Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate.

Mitcheson JS, Chen J, Sanguinetti MC.

J Gen Physiol. 2000 Mar;115(3):229-40.

37.

Biophysical properties and molecular basis of cardiac rapid and slow delayed rectifier potassium channels.

Mitcheson JS, Sanguinetti MC.

Cell Physiol Biochem. 1999;9(4-5):201-16. Review.

PMID:
10575198
39.

Cultured adult cardiac myocytes: future applications, culture methods, morphological and electrophysiological properties.

Mitcheson JS, Hancox JC, Levi AJ.

Cardiovasc Res. 1998 Aug;39(2):280-300. Review.

PMID:
9798514
40.

Ion channel and exchange currents in single myocytes isolated from the rabbit atrioventricular node.

Hancox JC, Mitcheson JS.

Can J Cardiol. 1997 Dec;13(12):1175-82. Review.

PMID:
9444299
42.

Cultured adult rabbit myocytes: effect of adding supplements to the medium, and response to isoprenaline.

Mitcheson JS, Hancox JC, Levi AJ.

J Cardiovasc Electrophysiol. 1997 Sep;8(9):1020-30.

PMID:
9300300
43.

Role of intracellular sodium overload in the genesis of cardiac arrhythmias.

Levi AJ, Dalton GR, Hancox JC, Mitcheson JS, Issberner J, Bates JA, Evans SJ, Howarth FC, Hobai IA, Jones JV.

J Cardiovasc Electrophysiol. 1997 Jun;8(6):700-21. Review.

PMID:
9209972
45.

Voltage dependence of the Fura-2 transient in rabbit left atrial myocytes at 37 degrees C.

Mitcheson JS, Hancox JC, Levi AJ.

Pflugers Arch. 1997 Apr;433(6):817-26.

PMID:
9049175
46.
47.

Supplemental Content

Loading ...
Support Center